Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.

Abstract

Disappointing results from most late-stage clinical trials of cancer therapeutics indicate a need for improved and more-predictive animal tumor models. This insufficiency of models, combined with the advent of a class of drugs that target the tumor microenvironment rather than the tumor cell, presents new challenges for designing and interpreting preclinical efficacy studies. A comparison of the clinical efficacy of anti-angiogenic drugs with their corresponding preclinical studies over the past two decades offers many lessons that can inform and improve the design of experiments in existing mouse models. In addition, technological and logistical advances in mouse models of human cancer over the past five years have the potential to increase the clinical translatability of animal studies.

• Authors: Mallika Singh, Napoleone Ferrara
• Journal: Nature biotechnology (Nat Biotechnol) Vol. 30 Issue 7 Pg. 648-57 (Jul 10 2012) ISSN: 1546-1696 [Electronic] United States
• PMID: 22781694 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Animals
• Cell Transformation, Neoplastic (drug effects)
• Clinical Trials as Topic
• Disease Models, Animal
• Drug Evaluation, Preclinical
• Humans
• Mice
• Neoplasms (drug therapy, pathology)
• Neovascularization, Pathologic (drug therapy, pathology)